Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant

Thumbnail Image
Files
Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant.pdf (77.11 KB)
Date
2014
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Journal of the International AIDS Society
Abstract
Sub-dermal hormone implants, such as levonorgestrel (LNG), are a safe and desirable form of long-acting contraception, but their use among HIV-positive women on antiretroviral therapy (ART) may be compromised given the potential for a cytochrome P450 3A-mediated drug-drug interaction. Our study aimed to characterize the pharmacokinetics of LNG released from a sub-dermal implant over six months in HIV-positive Ugandan women on nevirapine (NVP)- or efavirenz (EFV)-based ART.
Description
Keywords
Efavirenz, Nevirapine-based antiretroviral therapy, Levonorgestrel, Sub-dermal contraceptive implant
Citation
Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., ... & Back, D. (2014). Efavirenz‐but not nevirapine‐based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub‐dermal contraceptive implant. Journal of the International AIDS Society, 17, 19484. http://dx.doi.org/10.7448/IAS.17.4.19484
URI
http://dx.doi.org/10.7448/IAS.17.4.19484
 https://nru.uncst.go.ug/xmlui/handle/123456789/1214
Collections
Medical and Health Sciences